Case file
ReLife cough syrup (Shape Pharma)
Last checked 1 October 2026
ReLife is a cough syrup made by Shape Pharma in Gujarat that was found contaminated with diethylene glycol during the October 2025 investigations that followed the Coldrif deaths. It was named alongside Coldrif and Respifresh TR in WHO Medical Product Alert N°5/2025 on 13 October 2025. Gujarat suspended production at Shape Pharma, Telangana's Drugs Control Administration issued a public alert about the syrup, and Maharashtra's FDA issued a prohibition order on DEG-contaminated syrups. The WHO found no evidence that the product had been exported.
Status as of 1 October 2026
Maharashtra FDA: prohibition order on cough syrups with diethylene glycol
Scope. A record here does not by itself mean a product or company is unsafe or banned today. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Affected products and batches
| Product | Batch | Note |
|---|---|---|
| ReLife Syrup | Not stated | Diethylene glycol detected; percentage not in our sources |
Current status
Recalled; production suspended by Gujarat; covered by state prohibition orders as of 1 Oct 2026. No deaths have been publicly attributed specifically to ReLife in our sources.
What to do if you have this product
Step 1
Do not use ReLife syrup of any batch; return it to the pharmacy.
Step 2
Seek immediate care for a child with reduced urine, vomiting or drowsiness after taking any cough syrup.
Step 3
Do not give cough syrups to children under two.
Sources
Government documents
- WHO Medical Product Alert N°5/2025: Substandard (contaminated) oral liquid medicinesWHOWorld Health Organization · 13 October 2025
- Regulator
News reports
- Deccan Herald: After cough syrup deaths, Gujarat govt suspends operations of 2 pharma firmsNewsDeccan Herald
- Wikipedia: 2025 India cough syrup crisisCrowdsourcedWikipedia